Matthias Mueller – a:care Congress – Acare HCP Global
Skip to content
Home > Congress > Speakers > Dr. Matthias Mueller MD MSc

Dr. Matthias Mueller MD MSc

Switzerland

Dr. Matthias Mueller MD MSc, Divisional Vice President Innovation and Development, Abbott’s Established Pharmaceuticals business

Matthias Mueller heads Innovation and Development at Abbott’s Established Pharmaceuticals business. He leads a team of more than 1500 scientists and specialists worldwide that help deliver insight-driven, differentiated innovations to people in emerging countries.

Matthias has 20+ years of medical, clinical, research, and leadership expertise, overseeing several departments over his career at leading healthcare companies. He has led teams in Product Design and Development, Clinical Development and Operations, Pharmacovigilance and Patient Safety, and Regulatory and Medical Affairs.

A medical doctor by education, Matthias completed medical school, his residency, and his fellowship in the Department of Neurology at the University of Heidelberg, Germany, with a clinical and research focus on stroke and its prevention, epilepsy, and multiple sclerosis. Matthias specialized in Pharmaceutical Medicine at the University of Surrey, UK.

As a healthcare professional, he aims to make a meaningful difference in people’s lives so that more people in emerging countries can get and stay healthy.

Share this post

Read more on this topic

Session: Panel discussion - Sharing reflections and best practice

Session: Congress introduction second day

Session: Panel discussion - Raising adherence as a public health priority

Session: Closing congress first day

Session: Patient perspectives of adherence and how these can help us improve…

Session: International Society of Hypertension - Raising awareness on…

Session: International Society of Gynecological Endocrinology - From treating…

Session: Closing congress

Session: Practical individual interventions any healthcare professionals can…

Session: The challenge and causes of non-adherence

Session: Consequences of non-adherence to narrow therapeutic index drugs

Session: The paradox of non-adherence to treatment in oncology